Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Carcinoma, Hepatocellular 80Neoplasms 52Small Cell Lung Carcinoma 50Breast Neoplasms 50Lung Neoplasms 44Triple Negative Breast Neoplasms 41Melanoma 38Colorectal Neoplasms 38Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Neoplasm Metastasis 32Carcinoma, Renal Cell 29Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 14Prostatic Neoplasms 12Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Kidney Neoplasms 9Endometrial Neoplasms 9Mesothelioma, Malignant 8

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1atezolizumab 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Select Advanced Solid Tumors × atezolizumab × Clear all
NCT03973333 2024-10-18

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Immunocore Ltd

Phase 1/2 Withdrawn
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡